Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.09
- Piotroski Score 3.00
- Grade Buy
- Symbol (VCYT)
- Company Veracyte, Inc.
- Price $35.95
- Changes Percentage (2.77%)
- Change $0.97
- Day Low $34.41
- Day High $36.25
- Year High $36.25
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $26.00
- High Stock Price Target $26.00
- Low Stock Price Target $26.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.93
- Trailing P/E Ratio -22.2
- Forward P/E Ratio -22.2
- P/E Growth -22.2
- Net Income $-74,404,000
Income Statement
Quarterly
Annual
Latest News of VCYT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT)
Baron Funds released its Q2 2024 investor letter for the Baron Discovery Fund, highlighting Veracyte, Inc. (NASDAQ:VCYT). The stock showed strong performance with a 38.95% one-month return and a 27% i...
By Yahoo! Finance | 2 months ago -
Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT)
Director Jens Holstein sold 5,000 shares of Veracyte Inc on July 16, 2024, reducing his holdings to 32,878 shares. Veracyte specializes in genomic diagnostics, providing actionable results for patient...
By Yahoo! Finance | 3 months ago -
Market Sentiment Around Loss-Making Veracyte, Inc. (NASDAQ:VCYT)
Veracyte, Inc. is a diagnostics company aiming to reach profitability soon. Analysts predict the company will break even in 2024 and turn a profit in 2025, expecting a high growth rate....
By Yahoo! Finance | 4 months ago
